Icagen/J&J Terminate Phase III Sickle Cell Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Data monitoring committee advises low probability of achieving crisis reduction endpoint.
You may also be interested in...
Icagen CEO P. Kay Wagoner: An Interview With "The Pink Sheet" DAILY
Firm's leader discusses pipeline and partnership with Pfizer.
Icagen CEO P. Kay Wagoner: An Interview With "The Pink Sheet" DAILY
Firm's leader discusses pipeline and partnership with Pfizer.
J&J Terminates Icagen Deal For Senicapoc
Icagen says it will decide whether to continue development of the drug in sickle cell anemia by this fall.